Instability, stabilization, and formulation of liquid protein pharmaceuticals.

By Wei Wang. 1999

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Lyophilization and development of solid protein pharmaceuticals. (2000, background): “1993), co-solvents (Timasheff, 1993, 1998), or excipients (Wong and Parascrampuria, 1997; Wang, 1999).”
Protein aggregation: pathways, induction factors and analysis. (2009, background): “Melting temperatures vary among proteins, and lie usually in a range between 40 and 808C.(39) It is generally important to store biopharmaceuticals well below their Tm, usually at 2–88C, and to avoid processing temperatures for example during fermentation, purification and manufacturing that go abov”
Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles (2000, background): “In addition to PLGArelated degradation, one should be conscious of the various protein degradation routes that may occur in the aqueous state also in the absence of PLGA, as recently reviewed by Wang (65).”
Protein drug stability: a formulation challenge (2005, background): “The chemical and physical stability of proteins can be compromised by external factors such as pH, temperature and surface interaction, as well as by contaminants and impurities for excipients, and so o”